Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Dusseldorf - Delayed Quote • EUR Compass Pathways PLC (5Y6.DU) Follow Add holdings 3.3400 -0.0200 (-0.60%) At close: April 25 at 7:32:06 PM GMT+2 Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 5Y6.DU 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 5Y6.DU View More All News Press Releases SEC Filings Why Compass Pathways Stock Was a Double-Digit Winner This Week Psychedelic: Clearmind completes clinical site initiations for AUD trial Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression Psychedelic: Exclusive talk with biotech company Clearmind Medicine Psychedelic: atai Life Sciences, NRx report quarterly results Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression Compass Pathways to Participate in Stifel Virtual CNS Forum Compass one of the most compelling stories in neuropsych, says H.C. Wainwright COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025 Psychedelic: GH Research, Compass Pathways report earnings results